Drug Development Pharma - February 25, 2014
FDA approves Myalept to treat rare metabolic disease
The U.S. Food and Drug Administration has approved AstraZeneca’s and Bristol-Myers Squibb’s Myalept as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital generalized or acquired generalized lipodystrophy. The safety and effectiveness of Myalept, an analog of leptin made through recombinant DNA technology, were evaluated in an open-label, […]
